Kenvue shares recover after Trump's controversial statements on Tylenol

On Tuesday, the stock price of Tylenol manufacturer Kenvue saw a positive rebound after being pressured the previous day by statements from President Donald Trump. Trump had suggested a link between the painkiller Tylenol and autism during a White House press conference, without scientific basis, and advised pregnant women to avoid its consumption. These remarks led to a stock plunge for Kenvue on Monday, reaching a historic low. However, by pre-market trading on Tuesday, the stock price rose sharply, with an increase of up to six percent, after Trump failed to present new evidence for his claims. Accompanied by Health Secretary Robert F. Kennedy Jr., Trump emphasized that acetaminophen, the active ingredient in Tylenol, should only be used when medically necessary. Contrary to Trump's drastic recommendations, the U.S. Food and Drug Administration (FDA) recommended a more cautious approach and explained that while an association between acetaminophen and autism has been described in various studies, no causal link has been proven. Kenvue responded promptly, emphasizing that independent scientific findings do not confirm any link between acetaminophen and autism. The company expressed concern about the confusion and potential health risks for expectant mothers and parents. Economic analysts, including voices from Citi, were optimistic about a renewed upward movement of the stock, as the administration's claims had no scientific basis. A previous legal decision that dismissed a class action due to lack of evidence further underscored the limited legal risk for Kenvue. Professional medical associations sharply criticized Trump's statements. The association of autism researchers and the American College of Obstetricians and Gynecologists appealed that such misinformation stokes unnecessary fears and is considered misleading and irresponsible.